What is Rescheduling (Cannabis)?

Cannabis rescheduling refers to the process of changing marijuana's classification under the federal Controlled Substances Act (CSA). Currently, cannabis is classified as a Schedule I substance alongside heroin and LSD, indicating it has no accepted medical use and high potential for abuse. This classification has remained unchanged since the CSA's implementation in 1970. The rescheduling process involves several federal agencies, primarily the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA). The process can be initiated through petition by interested parties, congressional action, or agency recommendation. In May 2024, the DEA proposed moving cannabis from Schedule I to Schedule III, following a recommendation from the Department of Health and Human Services. Schedule III classification would place cannabis alongside substances like ketamine and anabolic steroids, recognizing accepted medical uses while maintaining regulatory oversight. This reclassification would have significant implications for the cannabis industry, potentially allowing businesses to claim federal tax deductions under Section 280E, which currently prohibits cannabis companies from deducting standard business expenses. Rescheduling differs from descheduling, which would remove cannabis entirely from the CSA. While rescheduling to Schedule III would provide regulatory relief, cannabis would remain federally controlled, and state-legal operators could still face federal enforcement. The economic impact could be substantial. Industry analysts estimate that Schedule III classification could save major cannabis companies millions in taxes annually. For example, multi-state operators like Curaleaf and Trulieve currently face effective tax rates exceeding 70% due to 280E restrictions. However, rescheduling faces political and regulatory challenges. The process requires extensive public comment periods, scientific review, and potential legal challenges. While recent polling shows majority American support for cannabis legalization, federal rescheduling timelines remain uncertain, with implementation potentially extending into 2025 or beyond, depending on regulatory review outcomes and potential administration changes.